HORIBA网络讲座|SPRI在抗体的运用——以阿尔茨海默的检测为例

This webinar will show the potentialities of the new multiplexing and fully automated SPRi "XelPleX" by illustrating

two examples of the simultaneous characterization of multiple biologically relevant interactions.

The first example represents the discovery and the study of the interaction between the endogenous antimicrobial peptide cathelicidin (LL37) and different beta-amyloid aggregation forms spotted onto the SPRi chip surface. This study confirms that cathelicidin is a binding partner of beta-amyloid and suggests its potential role as inhibitor of beta-amyloid fibrils.

The second example concerns the development and the optimization of a peptide microarray for the detection of circulating IgE antibodies in milk allergic patients. SPRi measurements permitted to select the best epitope presentation strategy (i.e. multiple epitope presentation) in order to obtain optimal analytical performances.

• Learning how the SPRi platform provides flexibility to scientists to engineer a wide range of assays for the detection of various analytes at real time, simultaneously and with high throughput

• Learn how to choose whether to perform kinetic or equilibrium SPR analyses

• Learn how to perform kinetic analyses of high-affinity antibody/antigen interactions

• Academic and industrial researchers working with and developing bioassays for a wide range of analytes.

• Scientists specializing or have expertise in the following fields: biomedical and clinical science, proteomics, genomics, biochemistry, ...

Dr Renzo Vanna, Researcher at IRCCS Fondazione Don Carlo Gnocchi, Laboratory of nanomedicine and clinical biophotonics (LABION),Milan, Italy Moderated by

Dr Chiraz Frydman, SPRi Product Manager at HORIBA Scientific

扫一扫▪查看更多详情▪报名